NASDAQ : KLRA
Kailera Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 12.67 USD (Oct 30, 2026, 2:47 PM EDT) · Market cap 1.64B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.67B |
| Enterprise Value | 505.62M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 23, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 129.64M |
| Shares Outstanding | 129.64M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +473,018.01% |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 44.69% |
| Float | 58.48M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.49 |
| P/TBV Ratio | 1.49 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 11.11 |
| Quick Ratio | 11.03 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -27.78% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.02M |
| Employee Count | 145 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 13.29 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 52.40 |
| Average Volume (20 Days) | 1,228,677 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 8.32M |
| Short Previous Month | 8.68M |
| Short % of Shares Out | 6.41% |
| Short % of Float | 14.22% |
| Short Ratio (days to cover) | 5.58 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -313.27M |
| Pretax Income | -292.20M |
| Net Income | -292.20M |
| EBITDA | -312.88M |
| EBIT | -313.27M |
| Earnings Per Share (EPS) | -$2.25 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 916.74M |
| Total Debt | 10.22M |
| Net Cash | 1.16B |
| Net Cash Per Share | $8.96 |
| Equity (Book Value) | 1.12B |
| Book Value Per Share | 8.63 |
| Working Capital | 845.52M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -221.62M |
| Capital Expenditures | -2.09M |
| Depreciation & Amortization | 387,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -223.70M |
| FCF Per Share | -$1.73 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -17.53% |
| FCF Yield | -13.42% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $42.75 |
| Price Target Difference | 232.43% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |